KANSAS CITY, Mo. — The University of Kansas Medical Center and Children's Mercy will be hosting a COVID-19 vaccine clinical trial.
The hospitals will be testing a vaccine called AZD1222 from AstraZeneca that was developed by Oxford University.
The phase 2/3 trial is funded by the National Institutes of Health and is expected to begin in mid-to-late August.
Multiple sites around the region will offer the vaccine trial to around 1,500 people. There will be 30,000 participants nationally.
Participants must be older than 18 and considered high-risk for coming into contact with COVID-19.
Two-thirds of participants will receive the vaccine and the other third will be given a placebo.
A pilot study found the vaccine to be promising and side effects were mild.
Anyone interested in the trial can register at the Coronavirus Prevention Network website and enter "KUMC" as the site.
